Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies - Subsequent Events (Details)

v3.26.1
Summary of Significant Accounting Policies - Subsequent Events (Details) - PRIDCor Therapeutics, LLC License Agreement - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2026
Sep. 30, 2026
Jun. 30, 2026
Summary of Significant Accounting Policies      
Revenue under the PRIDCor license agreement     $ 0
Subsequent event      
Summary of Significant Accounting Policies      
Minimum escrow break $ 1,000,000    
Revenue under the PRIDCor license agreement $ 100,000    
Cost of sales   $ 87,750